The CAR-T Therapy Shift: Redefining Second-Line Treatment Strategies in Multiple Myeloma : Episode 2

Managing Adverse Events with CAR T-Cell Therapy: Best Practices for Myeloma Care Teams

December 23, 2024

By Rahul Banerjee, MD, FACP
Saad Z. Usmani, MD, MBA, FACP, FASCO

Opinion

Video

EP: 1.Meet Sarah, a 55-year-old Businesswoman With Multiple Myeloma Considering CAR-T Therapy With Ide-cel

EP: 2.Managing Adverse Events with CAR T-Cell Therapy: Best Practices for Myeloma Care Teams

EP: 3.Managing Neurotoxicities in CAR T: Clinical Approaches and Patient/Caregiver Education

EP: 4.QOL Considerations for Optimal Patient Outcomes with CAR-T Therapy

EP: 5.Getting to Know Robert, a 72-Year-Old Retired Teacher Facing a Myeloma Relapse and Considering CAR-T Therapy with Cilta-cel

EP: 6.Long-Term CAR-T Management in Myeloma: Collaborative Care and Monitoring Strategies for Patients Like Robert

EP: 7.Life After CAR T Therapy: Insights for Patients and Referring Oncologists

Video content above is prompted by the following:

Let's start with an overview of the safety profile for CAR-T therapies in multiple myeloma.
What are the most common and significant adverse events you've observed with ide-cel and cilta-cel?

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos

Photo of a man wearing a suit in front of an Oncology Nursing News backdrop

2 experts are featured in this series.

2 experts are featured in this series.

Latest Conference Coverage

Safety Management With Amivantamab Plus Lazertinib in NSCLC

Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

Adverse Events of Menin Inhibitors in AML: What Nurses Should Know

Ivonescimab/Chemo Ups PFS After Third-Generation TKI in EGFR+ NSCLC

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences

All rights reserved.